Navigation Links
Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate

agel.

With today's results, Genzyme has concluded that the powder formulation of Renvela dosed three times per day may represent a promising alternative for patients with chronic kidney disease. The company will continue to move ahead aggressively with clinical and regulatory plans for the powder formulation dosed three times per day, and these data will form part of an NDA submission in the first half of 2008.

"We are very pleased with the progress we have made to date in our multi- faceted development program for Renvela, including filing an NDA for patients on dialysis, completing a successful trial in the pre-dialysis population, and demonstrating the effectiveness of the powder formulation dosed three times per day," said John P. Butler, president, Genzyme Renal. "Results of the once- per-day trial were greatly influenced by the strong phosphorus reduction seen in the Renagel arm, which was superior to that seen in all but one previously conducted clinical trials. While today's results will not currently support a regulatory filing for once-per-day dosing, they are clinically meaningful and give us confidence that this approach can be effective. We will continue to work with regulatory authorities to design an appropriate clinical plan to gain approval for this dosing regimen."

About Renvela

Renvela is a buffered form of Renagel, the most-prescribed phosphate binder in the United States. Like Renagel, Renvela is a calcium-free, metal- free, non-absorbed phosphate binder, and will be available as 800mg tablets once approved. A New Drug Application for Renvela is currently under review by the US Food and Drug Administration for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

In April, Genzyme announced that a new clinical trial showed that Renvela significantly reduced serum phosphorus, calcium-phosphorus product and LDL cholesterol in hyperphosphatemic patients with chronic kidney disease wh
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/7/2008)... In a clinical study of adults, VYVANSE taken ...ADHD within one week, PHILADELPHIA, Oct. 7 /PRNew...HPGY), the global specialty biopharmaceutical comp... September issue of the Journal of,Clinical Psychi...ed,Attention Deficit Hyperactivity Disorder (ADHD)...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Sci...ire-FirstCall/ -- Ironwood,Pharmaceuticals, Inc. (...Inc. (NYSE: FRX ) today announced the presentatio...lotide,s safety and efficacy in 420 patients with,.... Analysis of the data,indicates that once- daily ...
(Date:10/7/2008)... BERKELEY, Calif., Oct. 7 /- Aero... safety data from a Phase I trial of its Aerovant,...ty with no evidence of,local irritancy following a..., This 10 mg dose will be the highest of three do...ging study, which is scheduled to begin early,next...
(Date:10/7/2008)... 125 Patient, Prospective Randomized Placebo-Contr...Significant Improved Overall Survival., MOUNTAIN ...unoTherapeutics has now evaluated the mature Phase...ine candidate PROSTVAC(TM) that had been,obtained ...he National,Cancer Institute (NCI) in the US., Th...
Breaking Medicine Technology:Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 1Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 3Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 5Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 6Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 7Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 8Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 9Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 10Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 1Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 2Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 3Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 4Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 5Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 6ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo Including the Worlds Largest Catalog of Validated Ion C 3841 1ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo Including the Worlds Largest Catalog of Validated Ion C 3841 2Gender bias may affect care of people with osteoarthritis study finds 13976 1Gender bias may affect care of people with osteoarthritis study finds 13976 2
...7 - Novelos,Therapeutics, Inc. (OTCBB: NVLT), a bi... of therapeutics to treat cancer and,hepatitis, to...na-Farber/Partners Cancer Care (DF/PCC) Phase 2 tr...platinum-resistant ovarian,cancer patients. To dat...or response (assessed at least after 8 weeks / 2,c...
...m versus placebo: - 25,/ - 13 mm Hg (systolic / di...n vaccine dose and induced,antiangiotensin II anti... the Seventeenth European,Meeting on Hypertension ... and MILAN, Italy, June 17, 2007 -,Cytos Biotechno...ta,on its hypertension vaccine CYT006-AngQb at the...
Other Medicine Technology:Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care 2Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 2Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 4Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 5Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 6Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 7Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 8Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 9
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...ntists from the University of Cincinnati have come...ood obesity.// This issue has become an important...ety. In the spring season the researchers recruite...m in Meade County, Ky to fight childhood obesity. ...
...rding to the scientist from the Victorian Breast C...east stem cells which have undergone some mutation...ancers.// The Walter and Eliza Hall Institute res...en they found that the breast stem cells do not ex...
...w research conducted by consumer organization Whic...s contain high levels of fat, salt and sugar. Of...hecked for sugar, salt and fat content using the F...three-quarters had a high level of sugars, while a...
...recent announcements by Health Minister, Tony Abbo...ic health enemy No.1, has failed to impress AMA Pr...e initiatives to be much more forceful so that pro... The minister had announced a new ministerial t...
Other Medicine News:Health News:New Preventive Strategy to Fight Childhood Obesity 2Health News:Mutation in Breast Stem Cells Lead to Breast Cancer 2
...eica ASP200 is an advanced smart processor for par...ne histopathology applications. Proven and enhance... smart operating software are the hallmark of the ...ed and the software includes a variety of SMART fe...
The electronic, motorized rotary microtomes are designed for all applications of paraffin, semi-thin (HM 360), and hard specimens in clinical, research, and industrial labs. These instruments display
...eica RM2255 rotary microtome, designed for fully m...bedded specimens, offers a broad application spect...ory. This microtome meets the requirements of user...c microtome for their laboratory. The entire acces...
State-of-the-Art modular embedding station providing performance and ease of use to meet the needs of the most demanding user.
Medicine Products: